바이시클 테라퓨틱스(BCYC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.68 (+0.00%), 시가총액 $0.31B, 52주 최저~최고 $4.31 ~ $8.87.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for
바이시클 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
바이시클 테라퓨틱스의 현재 주가는 $3.68 (+0.00%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
바이시클 테라퓨틱스의 시가총액은 약 $0.31B입니다.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.